Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$0.6 - $0.9 $1,162 - $1,744
-1,938 Reduced 3.32%
56,355 $50,000
Q4 2023

Feb 12, 2024

BUY
$0.65 - $0.86 $6,008 - $7,949
9,244 Added 18.85%
58,293 $44,000
Q2 2023

Aug 11, 2023

BUY
$1.08 - $1.65 $52,972 - $80,930
49,049 New
49,049 $58,000
Q2 2022

Aug 15, 2022

SELL
$0.88 - $1.87 $28,783 - $61,165
-32,709 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$1.38 - $1.89 $993 - $1,360
720 Added 2.25%
32,709 $59,000
Q4 2021

Feb 14, 2022

SELL
$1.51 - $2.2 $34,116 - $49,706
-22,594 Reduced 41.39%
31,989 $49,000
Q3 2021

Nov 15, 2021

BUY
$1.74 - $2.6 $18,945 - $28,308
10,888 Added 24.92%
54,583 $110,000
Q2 2021

Aug 17, 2021

BUY
$1.51 - $4.23 $65,979 - $184,829
43,695 New
43,695 $152,000

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $457M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.